The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...

Nucala (mepolizumab) and Dupixent (dupilumab) are brand-name subcutaneous injections. They’re both prescribed for asthma and chronic rhinosinusitis with nasal polyps. Each drug may also be ...

The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.

Nucala isn’t known to interact with drugs, supplements, or alcohol. However, Nucala may cause certain vaccines to be less effective. Talk with your doctor to help avoid potentially harmful ...

GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or ...

GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking approval for a new indication of its respiratory drug, Nucala (mepolizumab).

Nucala (mepolizumab) is a prescription injection used to treat a type of asthma and other inflammatory conditions. Nucala isn’t known to interact with other drugs, alcohol, or supplements.

The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for individuals with chronic obstructive pulmonary ...

March 24 (Reuters) - The European Medicines Agency will review GSK's (GSK.L), opens new tab request to approve its asthma drug Nucala as an additional treatment for chronic obstructive pulmonary ...

GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...